Eli Lilly and Co. has filed a complaint with the U.S. International Trade Commission (ITC) against Hospira Inc., Intas Pharmaceuticals Ltd., and others, over attempts to introduce generic versions of the cancer drug Gemzar®. Lilly's complaint, filed Thursday, asks the ITC to launch an investigation into whether Hospira, Intas, Jiangsu Hansoh Pharmaceutical Co. Ltd., and Chem Werth Inc., have run afoul of Section 337 of the Tariff Act of 1930 in connection with the selling or importing of gemcitabine and gemcitabine-containing products that allegedly infringe Lilly's patent for Gemzar®. The complaint states that Hospira has contracts with the other three respondents to make and formulate a generic gemcitabine product for import and sale into the U.S., and requests permanent exclusion and cease-and-desist orders. Lilly is represented by Finnegan.